Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRECCAR14: Tailored Management of Locally-advanced Rectal Carcinoma After Induction Chemotherapy
NCT04749108Phase 3Recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Nov 2021
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, FOLFIRINOX in Rectal cancer (RC), sponsored by Institut du Cancer de Montpellier. Started Nov 2021; status: recruiting.
02
Drugs
capecitabineFOLFIRINOX
03
Conditions
Rectal cancer (RC)
Beyond the preview
Go deeper on NCT04749108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749108.